JNJonas Neuser

Jonas Neuser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jonas Neuser has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel self‐expanding ALLEGRA transcatheter aortic valve for native aortic stenosis and degenerated bioprosthesis

    by Jonas Neuser, Tibor Kempf, Johann Bauersachs, Julian D. Widder

    Objectives: To investigate the safety and efficacy of the ALLEGRA valve in routine use.Background: The ALLEGRA aortic valve is a self‐expanding transcatheter heart valve (THV) with bovine pericardial tissue and was CE approved in March 2017. Its unique design was developed to provide low prosthesis gradients.Methods: We analyzed patients receiving an ALLEGRA THV between May 2017 and March 2021 at our center for treatment of aortic valve stenosis or degenerated valve prosthesis. Hemodynamic results and clinical outcome according to the Valve Academic Research Consortium‐2 consensus criteria were evaluated at discharge and three months post transcatheter aortic valve replacement (TAVR) procedure. 93 patients with a mean age of 82.5 ± 4.8 years and a median EuroScore II of 4.7 ± 3.4 were treated, 15 of them were valve‐in‐valve procedures.Results: Implantation was successful in 97.8% (91/93) and VARC‐2 defined device success was achieved in 94.6% (88/93). In‐hospital all‐cause mortality was 2.2% (2/93). Life‐threatening bleeding, major vascular complications and strokes were 3.2% (3/93), 2.2% (2/93) and 3.2% (3/93), respectively. Paravalvular leakage was none to trace in 60.4%, mild in 38.5% and moderate in 1.1%. Permanent pacemaker implantation in pacemaker naive patients was necessary in 9.5% (8/84). Mean gradient at discharge was 8.2 ± 4.3 mmHg for all patients; 7.1 ± 2.6 mmHg in patients treated for stenosis of the native aortic valve and 13.8 ± 6.3 mmHg in patients treated valve‐in‐valve.Conclusions: The ALLEGRA THV provides excellent hemodynamic results and a good safety profile with a low complication rate.


  • Open Access

    Expansion of CD10 neg neutrophils and CD14 + HLA-DR neg/low monocytes driving proinflammatory responses in patients with acute myocardial infarction

    by Daniela Fraccarollo, Jonas Neuser, Julian Möller, Christian Riehle, Paolo Galuppo, Johann Bauersachs

    Immature neutrophils and HLA-DR neg/low monocytes expand in cancer, autoimmune diseases and viral infections, but their appearance and functional characteristics after acute myocardial infarction (AMI) remain underexplored. We found an expansion of circulating immature CD16 + CD66b + CD10 neg neutrophils and CD14 + HLA-DR neg/low monocytes in patients with AMI, correlating with cardiac damage, function and serum levels of immune-inflammation markers. Increased frequency of immature CD10 neg neutrophils and elevated circulating levels of IFN-γ were linked, mainly in cytomegalovirus (CMV)-seropositive patients with high anti-CMV antibody titers and expanded CD4 + CD28 null T-cells. At a mechanistic level, CD10 neg neutrophils enhance IFN-γ production by CD4 + T-cells through induction of interleukin-12. Moreover, we showed that HLA-DR neg/low monocytes are not immunosuppressive but secrete high levels of pro-inflammatory cytokines after differentiation to macrophages and IFN-γ stimulation. Thus, the immunoregulatory functions of immature CD10 neg neutrophils play a dynamic role in mechanisms linking myeloid cell compartment dysregulation, Th1-type immune responses and inflammation in patients with AMI.


  • Open Access

    Intermediate CD14++CD16+ monocytes decline after transcatheter aortic valve replacement and correlate with functional capacity and left ventricular systolic function

    by Jonas Neuser, Paolo Galuppo, Daniela Fraccarollo, Jens Willig, Tibor Kempf, Dominik Berliner, Johann Bauersachs, Julian Daniel Widder

    Transcatheter aortic valve replacement (TAVR) is the method of choice for patients with severe aortic valve stenosis, who are ineligible or at high risk for surgery. Though TAVR leads to a significant reduction in mortality, a notable amount of patients are re-hospitalized early after TAVR. Parameters or biomarkers predicting outcome are therefore needed to identify patients who benefit most. Specific monocyte subsets have been associated with cardiovascular diseases and were shown to possess prognostic value. Peripheral blood was drawn before and after transfemoral TAVR with the self-expanding CoreValve, Boston Lotus or the balloon-expanding Edwards Sapien prosthesis. Classical (CD14++CD16−), intermediate (CD14++CD16+) and non-classical (CD14+CD16++) monocyte subsets were determined by flow cytometry. Transthoracic echocardiography was performed before, early after as well as 3 months after the TAVR procedure. No significant differences in the absolute monocyte counts were found after TAVR. A significant decline in the intermediate monocyte population was though observed early after TAVR (pre 4.01±0.38%, post 2.803±0.34%, p≤0.05). Creatinine levels stayed stable after TAVR procedure and intermediate monocytes were associated with worse renal function. Monocyte decline was not related to changes in CRP-, noradrenaline, cortisol or aldosterone-levels. The amount of intermediate monocytes correlated with worse cardiac function and predicted the possibility to reach an improvement in NYHA functional class at 3 months after TAVR. A significant decline of intermediate monocytes occurs shortly after TAVR. High levels of intermediate monocytes were associated with worse cardiac function and predicted poor functional capacity, hinting at a possible prognostic value.